ArticleJournal of pain research2017
The prevalence of probable neuropathic pain in the US: results from a multimodal general-population health survey.
Article in Journal of pain research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06030297 (Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.), which is not on this map. Cited by 64 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.
Who cites it
64 citing papers in PubMed, 2 syntheses or guidelines pooled it, 137 citations in OpenAlex.
- The involvement and significance of M2 macrophages in neuropathic pain following spinal cord injury: a systematic review.The journal of physiological sciences : JPS · 2024Pooled it
- Acupuncture for neuropathic pain: A meta-analysis of randomized control trials.Frontiers in neurology · 2022Pooled it
- Trial
- Electrocatheter-mediated High-voltage Pulsed Radiofrequency of the Dorsal Root Ganglion in the Treatment of Chronic Lumbosacral Neuropathic Pain: A Randomized Controlled Study.The Clinical journal of pain · 2020Trial
- Intravenous lidocaine in the management of chronic peripheral neuropathic pain: a randomized-controlled trial.Canadian journal of anaesthesia = Journal canadien d'anesthesie · 2019Trial
- NYX-2925, A Novel N-methyl-D-aspartate Receptor Modulator: A First-in-Human, Randomized, Double-blind Study of Safety and Pharmacokinetics in Adults.Clinical and translational science · 2019Trial
- Addressing health inequities in treating neuropathic pain: a scoping review of cognitive behavioral therapies, mindfulness, and meditation-based interventions.Epidemiologic reviews · 2026Article
- Fabry disease in females: organ involvement and clinical outcomes compared with the general population (103/150 characters).Orphanet journal of rare diseases · 2025Review
- Opiorphin and neuropathic pain: a promising treatment approach?Inflammopharmacology · 2025Review
- The Role of TNF-α in Neuropathic Pain: An Immunotherapeutic Perspective.Life (Basel, Switzerland) · 2025Review
- A Mediation Appraisal of Neuropathic-like Symptoms, Pain Catastrophizing, and Central Sensitization-Related Signs in Adults with Knee Osteoarthritis-A Cross-Sectional Study.Journal of personalized medicine · 2025Article
- Mechanisms for reducing/eliminating chronic neuropathic pain with a focus on platelet-rich plasma.Experimental biology and medicine (Maywood, N.J.) · 2025Review
- Metabolic resilience governs sex-specific pain recovery during hormonal aging: a multi-omics study of neuropathy in mice.Frontiers in pain research (Lausanne, Switzerland) · 2025Article
- Discovery of Antinociceptive α9α10 Nicotinic Acetylcholine Receptor Antagonists by Stable Receptor Expression.ACS chemical biology · 2024Article
- Methylcobalamin as a candidate for chronic peripheral neuropathic pain therapy: review of molecular pharmacology actiona.The Korean journal of pain · 2024Review
- A Comprehensive Review of Safety, Efficacy, and Indications for the Use of Alpha-Lipoic Acid and Acetyl-L-Carnitine in Neuropathic Pain.Integrative medicine (Encinitas, Calif.) · 2024Review
- A Narrative Review of the Dorsal Root Ganglia and Spinal Cord Mechanisms of Action of Neuromodulation Therapies in Neuropathic Pain.Brain sciences · 2024Review
- Article
- Management of Neuropathic Pain with Neurectomy Combined with Dermal Sensory Regenerative Peripheral Nerve Interface (DS-RPNI).Seminars in plastic surgery · 2024Review
- UltramicronizedCurrent neuropharmacology · 2024Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prevalence of neuropathic pain (NeP) has been estimated within specific health conditions; however, there are no published data on its broad prevalence in the US. The current exploratory study addresses this gap using the validated PainDetect questionnaire as a screener for probable NeP in a general-population health survey conducted with a multimodal recruitment strategy to maximize demographic representativeness. MATERIALS AND
methodsAdult respondents were recruited from a combination of Internet panels, telephone lists, address lists, mall-based interviews, and store-receipt invitations using a random stratified-sampling framework, with strata defined by age, sex, and race/ethnicity. Older persons and minorities were oversampled to improve prevalence estimates. Results were weighted to match the total adult US population using US Census data. Demographic information was collected, and respondents who experienced physical pain in the past 12 months completed the PainDetect and provided additional pain history. A cutoff score of 19 or greater on the PainDetect was used to define probable NeP.
resultsA total of 24,925 respondents (average response rate 2.5%) provided demographic data (52.2% female, mean age 51.5 years); 15,751 respondents reported pain (63.7%), of which 2,548 (15.7%, 95% confidence interval 14.9%-16.5%) had probable NeP based on the PainDetect, which was 10% (95% confidence interval 9.5%-10.5%) of all respondents. Among those reporting pain, the prevalence of probable NeP among Blacks and Hispanics was consistently higher than Whites in each age- and sex group. The highest prevalence among those with pain was among male Hispanics 35-44 years (32.4%) and 45-54 years (24.2%) old. The most commonly used medications reported by those with probable NeP were nonsteroidal anti-inflammatory drugs (44.2%), followed by weak opioids (31.7%), antiepileptics (10.9%), and strong opioids (10.9%).
conclusionThis is the first study to provide an estimate of the prevalence of probable NeP in the US, showing significant variation by age and ethnicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.